Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Roche

Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data

The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.

Clinical Trials Research and Development Strategies

Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC

Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.

Clinical Trials ImmunoOncology

Roche Expects Better Xofluza Sales After New Indication

Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.      
Approvals Advertising, Marketing & Sales

Roche Ups Outlook, Sees Spark Buy By Year-End

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.  

 

Sales & Earnings Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register